Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

150 Annual Financial Statement Konzern-Jahresabschluss
5. Notes to the consolidated income statement
5.1. Sales revenues
Sales revenue 2009 / 2010
Euro
Total sales revenue 43,643,832
Sales revenue to affiliates (13,260,105)
Group sales revenue to third parties 30,383,727
2008 / 2009
Euro
45,105,015
(14,585,753)
30,519,262
Sales are mainly generated through the sale of lasers and the corresponding laser probes / optical fibres
as well as the sale of pharma products.
5.2. Other operating income and expenses
Other operating income refers primarily to income from the liquidation of provisions, liquidation of
valuation reserves on claims and the disposal of fixed assets. Furthermore subsidies from public institutions
amounting to KEUR 1,161 (previous year: KEUR 381) are included.
Other operating expenses include primarily expenses for allocation of reserves, deprecation costs and
losses due to disposal of assets.
The income/expense from currency conversion is recorded in the income statement.
5.3. Selling and marketing expenses
2009 / 2010
Euro
biolitec AG 3,456,327
biolitec USA 2,667,107
CO 1,816,894
biolitec Pharma Ireland 714,195
CO USA 643,054
biolitec Italy 624,895
Others 989,265
10,911,737
2008 / 2009
Euro
4,815,065
4,322,723
1,906,099
1,076,544
824,784
682,517
1,380,404
15,008,136